ITCI Stock Overview
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States.
Intra-Cellular Therapies Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$42.66|
|52 Week High||US$55.20|
|52 Week Low||US$28.40|
|1 Month Change||-17.41%|
|3 Month Change||-0.93%|
|1 Year Change||28.03%|
|3 Year Change||243.76%|
|5 Year Change||214.37%|
|Change since IPO||326.60%|
Recent News & Updates
We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Intra-Cellular's Second FDA Win Makes It A Great Long-Term Investment
Intra-Cellular Therapies received FDA approval of CAPLYTA for the treatment of adults with bipolar depression. Total revenues of CAPLYTA in Q3 2021 for treatment of adults with Schizophrenia surged by 200% to $22.1 million compared to the same time period in the prior year. Two late-stage studies, Study '501 and Study '502, are using CAPLYTA as an adjunctive treatment for patients with major depressive disorder. Both studies are estimated to be completed end-2023. Intra-Cellular Therapies had $478.7 million in cash as of September 30, 2021; enough cash to fund operations for at least next 12 months of SEC Filing date November 9, 2021.
|ITCI||US Pharmaceuticals||US Market|
Return vs Industry: ITCI exceeded the US Pharmaceuticals industry which returned 5.3% over the past year.
Return vs Market: ITCI exceeded the US Market which returned 4.2% over the past year.
|ITCI Average Weekly Movement||9.9%|
|Pharmaceuticals Industry Average Movement||10.6%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: ITCI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ITCI's weekly volatility (10%) has been stable over the past year.
About the Company
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders.
Intra-Cellular Therapies Fundamentals Summary
|ITCI fundamental statistics|
Is ITCI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ITCI income statement (TTM)|
|Cost of Revenue||US$80.32m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.81|
|Net Profit Margin||-367.06%|
How did ITCI perform over the long term?See historical performance and comparison
Is Intra-Cellular Therapies undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ITCI ($42.66) is trading below our estimate of fair value ($422.07)
Significantly Below Fair Value: ITCI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ITCI is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: ITCI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ITCI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ITCI is overvalued based on its PB Ratio (8.1x) compared to the US Pharmaceuticals industry average (2.1x).
How is Intra-Cellular Therapies forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ITCI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: ITCI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ITCI's is expected to become profitable in the next 3 years.
Revenue vs Market: ITCI's revenue (42.5% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: ITCI's revenue (42.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ITCI is forecast to be unprofitable in 3 years.
How has Intra-Cellular Therapies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ITCI is currently unprofitable.
Growing Profit Margin: ITCI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ITCI is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
Accelerating Growth: Unable to compare ITCI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ITCI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: ITCI has a negative Return on Equity (-53.23%), as it is currently unprofitable.
How is Intra-Cellular Therapies's financial position?
Financial Position Analysis
Short Term Liabilities: ITCI's short term assets ($533.2M) exceed its short term liabilities ($49.9M).
Long Term Liabilities: ITCI's short term assets ($533.2M) exceed its long term liabilities ($20.3M).
Debt to Equity History and Analysis
Debt Level: ITCI is debt free.
Reducing Debt: ITCI has no debt compared to 5 years ago when its debt to equity ratio was 31%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ITCI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ITCI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Intra-Cellular Therapies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ITCI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ITCI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ITCI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ITCI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ITCI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sharon Mates (68 yo)
Dr. Sharon Mates, Ph D., co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and has been its Chairman, President and Chief Executive Officer since June 2002. Earlier in her career, Dr. Mates...
CEO Compensation Analysis
Compensation vs Market: Sharon's total compensation ($USD5.48M) is about average for companies of similar size in the US market ($USD5.28M).
Compensation vs Earnings: Sharon's compensation has increased whilst the company is unprofitable.
Experienced Management: ITCI's management team is considered experienced (4.8 years average tenure).
Experienced Board: ITCI's board of directors are considered experienced (8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.2%.
Intra-Cellular Therapies, Inc.'s employee growth, exchange listings and data sources
- Name: Intra-Cellular Therapies, Inc.
- Ticker: ITCI
- Exchange: NasdaqGS
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$3.939b
- Shares outstanding: 92.33m
- Website: https://www.intracellulartherapies.com
Number of Employees
- Intra-Cellular Therapies, Inc.
- 430 East 29th Street
- Suite 900
- New York
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/23 23:14|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.